Advanced Enzyme (ADVENZYMES) | Financial Analysis & Statements
Advanced Enzyme Technologies Ltd. Small-cap Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.9B
Gross Profit
1.4B
73.08%
Operating Income
468.1M
25.18%
Net Income
404.4M
21.75%
EPS (Diluted)
₹3.57
Balance Sheet Metrics
Total Assets
16.2B
Total Liabilities
1.5B
Shareholders Equity
14.7B
Debt to Equity
0.10
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Advanced Enzyme Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 6.4B | 6.2B | 5.4B | 5.3B | 5.0B |
| Cost of Goods Sold | 1.6B | 1.6B | 1.4B | 1.2B | 1.1B |
| Gross Profit | 4.7B | 4.6B | 4.0B | 4.1B | 3.9B |
| Gross Margin % | 74.1% | 74.4% | 73.6% | 77.4% | 78.9% |
| Operating Expenses | |||||
| Research & Development | 8.8M | 8.1M | 8.1M | 6.5M | 6.3M |
| Selling, General & Administrative | 426.1M | 397.2M | 379.1M | 354.8M | 243.8M |
| Other Operating Expenses | 816.3M | 793.6M | 752.4M | 619.0M | 475.8M |
| Total Operating Expenses | 1.3B | 1.2B | 1.1B | 980.3M | 725.8M |
| Operating Income | 1.6B | 1.7B | 1.4B | 1.7B | 2.1B |
| Operating Margin % | 25.2% | 27.7% | 25.6% | 31.9% | 41.9% |
| Non-Operating Items | |||||
| Interest Income | 198.1M | 133.3M | 94.8M | 4.0M | 5.8M |
| Interest Expense | 35.6M | 29.3M | 24.2M | 18.0M | 16.1M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.9B | 1.9B | 1.4B | 1.7B | 2.1B |
| Income Tax | 533.9M | 508.7M | 365.2M | 472.6M | 588.4M |
| Effective Tax Rate % | 28.5% | 27.1% | 26.0% | 27.6% | 28.0% |
| Net Income | 1.3B | 1.4B | 1.0B | 1.2B | 1.5B |
| Net Margin % | 21.0% | 22.0% | 19.2% | 23.4% | 30.2% |
| Key Metrics | |||||
| EBITDA | 2.2B | 2.3B | 1.9B | 2.1B | 2.4B |
| EPS (Basic) | ₹11.72 | ₹11.92 | ₹9.45 | ₹10.70 | ₹13.06 |
| EPS (Diluted) | ₹11.71 | ₹11.92 | ₹9.45 | ₹10.68 | ₹13.04 |
| Basic Shares Outstanding | 111852146 | 111824075 | 111815999 | 111777150 | 111696500 |
| Diluted Shares Outstanding | 111852146 | 111824075 | 111815999 | 111777150 | 111696500 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Advanced Enzyme Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 942.2M | 1.1B | 964.2M | 2.7B | 1.9B |
| Short-term Investments | 5.0B | 4.3B | 3.9B | 1.1B | 1.3B |
| Accounts Receivable | 1.2B | 985.7M | 1.0B | 882.1M | 862.7M |
| Inventory | 1.6B | 1.5B | 1.2B | 1.2B | 938.8M |
| Other Current Assets | 13.7M | 17.3M | 9.7M | 4.7M | 4.0M |
| Total Current Assets | 8.8B | 8.1B | 7.2B | 6.0B | 5.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.9B | 2.8B | 2.7B | 2.6B | 183.5M |
| Goodwill | 7.2B | 7.1B | 7.0B | 6.6B | 6.5B |
| Intangible Assets | 523.1M | 582.9M | 608.8M | 663.1M | 746.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 300.0K | 300.0K | 850.0K | 840.0K | 520.0K |
| Total Non-Current Assets | 7.4B | 7.3B | 7.0B | 6.7B | 6.4B |
| Total Assets | 16.2B | 15.4B | 14.2B | 12.7B | 11.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 172.0M | 157.6M | 242.2M | 179.0M | 152.2M |
| Short-term Debt | 184.3M | 244.9M | 111.2M | 82.5M | 141.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 85.3M | 135.9M | 105.2M | 97.8M | 130.1M |
| Total Current Liabilities | 967.6M | 1.1B | 775.7M | 604.2M | 675.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 209.2M | 228.2M | 223.8M | 264.8M | 137.9M |
| Deferred Tax Liabilities | 336.3M | 343.2M | 372.3M | 392.5M | 408.5M |
| Other Non-Current Liabilities | - | - | - | - | -10.0K |
| Total Non-Current Liabilities | 559.2M | 580.3M | 601.1M | 668.0M | 560.0M |
| Total Liabilities | 1.5B | 1.6B | 1.4B | 1.3B | 1.2B |
| Equity | |||||
| Common Stock | 223.8M | 223.6M | 223.6M | 223.6M | 223.5M |
| Retained Earnings | 11.5B | 10.8B | 10.0B | 9.1B | 8.0B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 14.7B | 13.7B | 12.8B | 11.4B | 10.3B |
| Key Metrics | |||||
| Total Debt | 393.5M | 473.1M | 335.0M | 347.3M | 279.6M |
| Working Capital | 7.8B | 7.0B | 6.4B | 5.4B | 4.5B |
Balance Sheet Composition
Advanced Enzyme Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.9B | 1.9B | 1.4B | 1.7B | 2.1B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 34.5M | 30.3M | 0 | 0 | 3.8M |
| Working Capital Changes | -144.8M | -263.3M | -55.5M | -296.6M | -155.3M |
| Operating Cash Flow | 1.7B | 1.5B | 1.3B | 1.4B | 1.9B |
| Investing Activities | |||||
| Capital Expenditures | -332.8M | -421.6M | -378.5M | -268.2M | -193.0M |
| Acquisitions | - | - | - | 0 | -16.3M |
| Investment Purchases | -647.9M | -304.3M | -2.7B | -2.4M | -58.9M |
| Investment Sales | - | - | 0 | 221.0M | - |
| Investing Cash Flow | -980.7M | -725.9M | -3.1B | -49.6M | -268.1M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -590.3M | -567.1M | -125.4M | -118.6M | -79.8M |
| Debt Issuance | 22.3M | - | 0 | 6.7M | 80.2M |
| Debt Repayment | -58.1M | -6.5M | -3.2M | -23.2M | -236.9M |
| Financing Cash Flow | -680.4M | -502.6M | -169.0M | -406.9M | -265.4M |
| Free Cash Flow | 1.1B | 940.6M | 1.0B | 941.2M | 1.4B |
| Net Change in Cash | 41.4M | 316.4M | -1.9B | 964.7M | 1.4B |
Cash Flow Trend
Advanced Enzyme Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
22.00
Forward P/E
19.30
Price to Book
2.26
Price to Sales
4.72
PEG Ratio
1.68
Profitability Ratios
Profit Margin
21.46%
Operating Margin
22.76%
Return on Equity
8.93%
Return on Assets
8.09%
Financial Health
Current Ratio
8.75
Debt to Equity
2.26
Beta
0.45
Per Share Data
EPS (TTM)
₹13.60
Book Value per Share
₹132.60
Revenue per Share
₹63.40
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ADVENZYMES | 33.4B | 22.00 | 2.26 | 8.93% | 21.46% | 2.26 |
| Asian Paints | 2.4T | 62.11 | 12.16 | 18.28% | 11.10% | 17.61 |
| Pidilite Industries | 1.4T | 62.22 | 14.87 | 20.85% | 16.19% | 4.54 |
| Tanfac Industries | 49.6B | 66.26 | 14.61 | 28.25% | 10.85% | 9.28 |
| Gulf Oil Lubricants | 48.1B | 13.85 | 2.91 | 23.50% | 8.88% | 29.57 |
| Neogen Chemicals | 44.8B | 222.22 | 5.46 | 4.41% | 2.41% | 141.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.





